These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38725133)

  • 1. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support.
    Li S; Li A; Beckman JA; Kim C; Granich MA; Mondin J; Sabath DE; Garcia DA; Mahr C
    ESC Heart Fail; 2024 Oct; 11(5):2742-2748. PubMed ID: 38725133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
    Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
    J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance among assays for monitoring? Anticoagulation during extracorporeal life support.
    Scott EJ; Rotar E; Dahl JJ; Beller JP; Money DT; Chancellor WZ; Mehaffey JH; Morisette M; Yarboro LT; Teman NR
    Perfusion; 2023 Nov; 38(8):1714-1721. PubMed ID: 36167522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
    Monteagudo-Vela M; Bowles C; Raj B; Robinson D; Simon A
    Interact Cardiovasc Thorac Surg; 2022 Jan; 34(2):322-325. PubMed ID: 34849924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudo Heparin Resistance After Pulmonary Endarterectomy: Role of Thrombus Production of Factor VIII.
    Nykänen AI; Selby R; McRae KM; Zhao Y; Asghar UM; Donahoe L; Granton J; de Perrot M
    Semin Thorac Cardiovasc Surg; 2022; 34(1):315-323. PubMed ID: 33984481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial.
    Aubron C; Chapalain X; Bailey M; Board J; Buhr H; Cartwright B; Dennis M; Hodgson C; Forrest P; McIlroy D; Murphy D; Murray L; Pellegrino V; Pilcher D; Sheldrake J; Tran H; Vallance S; Cooper DJ; McQuilten Z
    Crit Care Explor; 2023 Nov; 5(11):e0999. PubMed ID: 37954899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardization of Anti-Xa Assay and its Comparison with Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin Therapy.
    Thalappil V; Anand J; Keepanasseril A; Kar R
    Indian J Hematol Blood Transfus; 2024 Jul; 40(3):432-436. PubMed ID: 39011243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
    Rizk E; Wilson AD; Murillo MU; Putney DR
    Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
    Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
    R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we abandon the APTT for monitoring unfractionated heparin?
    Arachchillage DRJ; Kamani F; Deplano S; Banya W; Laffan M
    Thromb Res; 2017 Sep; 157():157-161. PubMed ID: 28759760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation.
    Vo T; Bello A; Ragan M; Flanagan J; Johnson D
    Am J Health Syst Pharm; 2023 May; 80(Suppl 2):S77-S83. PubMed ID: 36478046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.